Company

Medigene (FSE: MDG1) is a publicly listed, early-stage biotech company focused on developing differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications.

TCR-T expertise is the foundation for our integrated proprietary “end-to-end” platform which allows for product enhancement and development technologies.

Company Strategy

Medigene’s strategy is to develop its therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the Company offers selected partners the opportunity to discover and develop additional therapies by accessing Medigene’s proprietary ‘End-to-end’ platform that includes enhancement technologies (like our PD1-41BB costimulatory switch receptor) and optimization technologies (like our Allo-HLA priming).

Focus on T-cell-directed immunotherapies

Focus on T-cell-directed immunotherapies

Roughly 80 employees with expertise in immunotherapy and pharmaceutical development

Roughly 80 employees with expertise in immunotherapy and pharmaceutical development

Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California

Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California

Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00

Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00

Company History

Comprehensive research and development partnership with BioNTech
Publication of topline data of the Phase I/II study of MDG1011 in AML and MDS
Publication of topline data of the DC vaccine trial (FDC101)
Sale of remaining rights and inventories of Veregen®
Roivant and Sinovant launch Cytovant Sciences in partnership with Medigene to develop cellular therapies in Asia
Start of the Phase I/II study of MDG1011 in AML and MDS
Expansion of the bluebird bio partnership
U.S.-rights for Veregen® are disposed
bluebird bio and Medigene establish strategic T cell receptor alliance in cancer immunotherapy
Start of Phase II part of the clinical trial with DC vaccine (FDC101)
Amgen acquires Medigene spin-off Catherex
Start of Phase I/II clinical trial with DC vaccine (FDC101) to treat AML
Focus on immuno-oncology by acquisition of Trianta Immunotherapies (renamed Medigene Immunotherapies)
Strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex®
Medigene’s product Veregen® became the first FDA-approved biopharmaceutical of a German biotech company in the USA
Medigene acquired British biotechnology company Avidex Limited
Medigene received first regulatory approval for cancer drug Eligard® in Germany
Medigene acquired products and technology of Munich Biotech AG
Medigene acquired US biotechnology company NeuroVir
Medigene IPO listed on the Frankfurt Stock Exchange
Medigene founded as Munich Gene Center spin-off
2022
2021
2020
2019
2019
2018
2018
2017
2016
2016
2015
2015
2014
2012-2014
2006
2006
2004
2004
2001
2000
1994
This site is registered on wpml.org as a development site.